市場調査レポート

商品コード

1156748

移植診断の世界市場：業界動向と予測（～2029年）

Global Transplant Diagnostics Market - Industry Trends and Forecast to 2029

出版日: 2022年10月01日 | 発行: Data Bridge Market Research

| ページ情報: 英文 699 Pages | 納期: お問合せ

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License) - Printable/Downloadable

USD 4,800 751,584円

レポートPDFを1名様のみご使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License) - Printable/Downloadable

USD 7,000 1,096,060円

レポートPDFを同一企業内すべての方にご使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.58円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の移植診断の市場規模は、2022年～2029年の予測期間に6.8%のCAGRを記録すると予測されています。

移植分野における技術進歩の増加、世界の移植手術件数の上昇などが、市場成長の主要な促進要因です。

当レポートでは、世界の移植診断市場について調査分析し、市場概要、セグメント別・地域別の市場分析、競合分析、企業プロファイルなど、体系的な情報を提供しています。

促進要因
- 移植手術件数の上昇
- 移植分野における技術進歩の増加
- 医療費の支出拡大
- 移植前・移植後のクロスマッチング・キメリズム検査の採用
抑制要因
- 臓器移植の高額な費用
- 臓器移植のリスクと難しさ
機会
- 市場企業による戦略的イニシアチブ
- 公共・民間・政府による臓器移植への投資増大
- 臓器移植の重要性に対する意識の高まり
課題
- 臓器移植時に直面する倫理的課題
- 臓器提供者の不足や、臓器提供者と臓器の年間必要数とのギャップ

第8章世界の移植診断市場：製品タイプ

概要
移植診断器具
- 自動ピペッター・ディスペンサー
- 自動化システム
- NGS機器
- リーダー・アナライザー
- 移植診断キット
- その他のキット
移植診断ソフトウェア
- DNAソフトウェア
- NGSソフトウェア
- データ管理ソフトウェア
- その他のソフトウェア
移植診断試薬
- モノクローナル抗体
- 細胞毒性コントロール
- ヒト血清
- その他の試薬

第9章世界の移植診断市場：技術別

概要
PCRベース分子アッセイ
- リアルタイムPCR
- 配列特異的プライマーPCR
- 配列特異的オリゴヌクレオチドPCR
- 制限断片長多型（RFLP）
- その他のPCRベース分子アッセイ
シーケンスベース分子アッセイ
- サンガーシーケンシング
- 次世代シーケンシング
- その他のシーケンスベース分子アッセイ

第10章世界の移植診断市場：移植タイプ別

概要
固形臓器移植
- 腎臓移植
- 肝移植
- 心臓移植
- 肺移植
- 膵臓移植
- その他の臓器移植
幹細胞移植
- 骨髄移植（BMT）
- 末梢血幹細胞移植
- 臍帯血移植
- その他の幹細胞移植
軟組織移植
- 皮膚移植
- 軟骨移植
- 副腎自家移植
- その他の軟組織移植
骨髄移植
- 自己骨髄移植
- 同種骨髄移植
- 臍帯血移植
その他

第11章世界の移植診断市場：用途別

概要
診断用途
- 移植診断器具
- 移植診断ソフトウェア
- 移植診断試薬
研究用途
- 移植診断器具
- 移植診断ソフトウェア
- 移植診断試薬

第12章世界の移植診断市場：エンドユーザー別

概要
病院・移植センター
商業サービスプロバイダー
研究所・学術機関
その他

第13章世界の移植診断市場：流通チャネル別

概要
直接入札
小売
その他

第14章世界の移植診断市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
アジア太平洋
- 中国
- 日本
- 韓国
- インド
- オーストラリア
- シンガポール
- タイ
- マレーシア
- インドネシア
- フィリピン
- その他アジア太平洋
欧州
- ドイツ
- フランス
- 英国
- イタリア
- ロシア
- スペイン
- トルコ
- オランダ
- スイス
- ベルギー
- その他欧州
南米
- ブラジル
- アルゼンチン
- その他南米
中東・アフリカ
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- エジプト
- イスラエル
- その他中東・アフリカ

第15章世界の移植診断市場：企業情勢

企業シェア分析：世界
企業シェア分析：北米
企業シェア分析：欧州
企業シェア分析：アジア太平洋

第16章 SWOT分析

第17章企業プロファイル

ABBOTT
THERMO FISHER SCIENTIFIC INC.
F. HOFFMANN LA ROCHE LTD
TAKARA BIO INC.
HOLOGIC, INC
ADAPTIVE BIOTECHNOLOGIES
ALTONA DIAGNOSTICS
ARQUER DIAGNOSTICS LTD
BAG DIAGNOSTICS GMBH
BIOFORTUNA LIMITED
BIOMERIEUX
BIO-RAD LABORATORIES, INC.
BIOTYPE GMBH
CAREDX INC.
CLONIT SRL
DIAGNOSTICA LONGWOOD SL
DIASORIN S.P.A.
ELITECHGROUP
EUROFINS VIRACOR
HORIBA LTD
ILLUMINA, INC.
IMMUCOR
LABORATORY CORPORATION OF AMERICA HOLDINGS.
LUMINEX CORPORATION.（A SUBSIDIARY OF DIASORIN）
NANOSTRING
PATHONOSTICS
PRESERVATION SOLUTIONS, INC.
QIAGEN
RANDOX LABORATORIES LTD.
STRYKER
TRANSMEDICS
TRANSONIC.
ZIMMER BIOMET

第18章アンケート

第19章関連レポート

図表

LIST OF FIGURES

FIGURE 1 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: SEGMENTATION 84
FIGURE 2 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: DATA TRIANGULATION 87
FIGURE 3 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: DROC ANALYSIS 88
FIGURE 4 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 89
FIGURE 5 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 89
FIGURE 6 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 90
FIGURE 7 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 92
FIGURE 8 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 94
FIGURE 9 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 95
FIGURE 10 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: SEGMENTATION 99
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET, AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 100
FIGURE 12 INCREASING USE OF TRANSPLANT DIAGNOSTICS IS EXPECTED TO DRIVE THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET IN THE FORECAST PERIOD 101
FIGURE 13 TRANSPLANT DIAGNOSTIC INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET IN 2022 & 2029 101
FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR TRANSPLANT DIAGNOSTICS MANUFACTURERS IN THE FORECAST PERIOD 102
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET 129
FIGURE 16 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2021 137
FIGURE 17 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION) 138
FIGURE 18 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2022-2029) 138
FIGURE 19 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 139
FIGURE 20 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, 2021 148
FIGURE 21 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022-2029 (USD MILLION) 149
FIGURE 22 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2022-2029) 149
FIGURE 23 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE 150
FIGURE 24 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, 2021 155
FIGURE 25 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, 2022-2029 (USD MILLION) 156
FIGURE 26 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, CAGR (2022-2029) 156
FIGURE 27 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, LIFELINE CURVE 157
FIGURE 28 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, 2021 165
FIGURE 29 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, 2022-2029 (USD MILLION) 166
FIGURE 30 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2022-2029) 166
FIGURE 31 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE 167
FIGURE 32 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY END USER, 2021 177
FIGURE 33 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY END USER, 2022-2029 (USD MILLION) 178
FIGURE 34 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY END USER, CAGR (2022-2029) 178
FIGURE 35 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 179
FIGURE 36 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2021 183
FIGURE 37 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 184
FIGURE 38 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 184
FIGURE 39 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 185
FIGURE 40 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 190
FIGURE 41 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY REGION (2021) 191
FIGURE 42 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY REGION (2022 & 2029) 191
FIGURE 43 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY REGION (2021 & 2029) 192
FIGURE 44 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 192
FIGURE 45 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 195
FIGURE 46 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021) 196
FIGURE 47 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029) 196
FIGURE 48 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029) 197
FIGURE 49 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 197
FIGURE 50 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 243
FIGURE 51 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021) 244
FIGURE 52 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029) 244
FIGURE 53 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029) 245
FIGURE 54 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 245
FIGURE 55 EUROPE TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 378
FIGURE 56 EUROPE TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021) 379
FIGURE 57 EUROPE TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029) 379
FIGURE 58 EUROPE TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029) 380
FIGURE 59 EUROPE TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 381
FIGURE 60 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 514
FIGURE 61 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021) 515
FIGURE 62 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029) 515
FIGURE 63 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029) 516
FIGURE 64 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 516
FIGURE 65 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 551
FIGURE 66 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021) 552
FIGURE 67 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029) 552
FIGURE 68 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029) 553
FIGURE 69 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 553
FIGURE 70 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%) 624
FIGURE 71 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%) 625
FIGURE 72 EUROPE TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%) 626
FIGURE 73 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%) 627

Global transplant diagnostics market is projected to register a CAGR of 6.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2022 to 2029.

Market Segmentation:

Global Transplant Diagnostics Market, By Product Type (Transplant Diagnostic Instrument, Transplant Diagnostic Software, Transplant Diagnostic Reagent), Technology (PCR-Based Molecular Assays, Sequencing-Based Molecular Assays), Transplant Type (Solid Organ Transplantation, Stem Cell Transplantation, Soft Tissue Transplantation, Bone Marrow Transplantation, Other Transplants), Application (Diagnostic Applications, Research Applications), End User (Research Laboratories and Academic Institutes, Hospital and Transplant Centers, Commercial Service Providers, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (U.S., Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and the Rest of Europe, China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Philippines, Indonesia, and the Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, and the Rest of the Middle East and Africa) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the global transplant diagnostics market are:

Increase in the technological advancements in the field of transplant

Rising number of transplant procedures globally

Market Players:

Some of the major players operating in the global transplant diagnostics market are:

Hologic, Inc.

Biofortuna Limited

Takara Bio Inc.

Abbott

Diagnostica Longwood SL

Adaptive Biotechnologies

NanoString

Arquer Diagnostics Ltd

altona Diagnostics GmbH

ELITechGroup

DiaSorin S.p.A.

Horiba Ltd

EUROFINS VIRACOR

CareDx Inc.

Laboratory Corporation of America Holdings.

Randox Laboratories Ltd.

Thermo Fisher Scientific Inc.

Preservation Solutions, Inc.

TransMedics

Transonic

Stryker

Bio-Rad Laboratories, Inc.

Zimmer Biomet

QIAGEN

F. Hoffmann-La Roche Ltd

BIOMERIEUX

Illumina, Inc.

Luminex Corporation (A subsidiary of DiaSorin Company)

IMMUCOR

CLONIT srl

PathoNostics

Biotype GmbH

BAG Diagnostics GmbH

1 INTRODUCTION 75

1.1 OBJECTIVES OF THE STUDY 75
1.2 MARKET DEFINITION 75
1.3 OVERVIEW OF THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET 75
1.4 CURRENCY AND PRICING 78
1.5 LIMITATIONS 78
1.6 MARKETS COVERED 78

2 MARKET SEGMENTATION 84

2.1 MARKETS COVERED 84
2.2 GEOGRAPHICAL SCOPE 85
2.3 YEARS CONSIDERED FOR THE STUDY 86
2.4 DBMR TRIPOD DATA VALIDATION MODEL 87
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 90
2.6 MULTIVARIATE MODELLING 91
2.7 MARKET APPLICATION COVERAGE GRID 92
2.8 SOURCE LIFELINE CURVE 93
2.9 DBMR MARKET POSITION GRID 94
2.10 VENDOR SHARE ANALYSIS 95
2.11 SECONDARY SOURCES 96
2.12 ASSUMPTIONS 96

3 EXECUTIVE SUMMARY 97

3.1 EPIDEMOLOGY 103
3.2 PESTEL_ANALYSIS 118
3.3 PORTER'S FIVE FORCE 119
3.4 TECHNOLOGICAL INNOVATIONS 120

4 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: REGULATIONS 121

5 KEY STRATEGIC INITIATIVES 125

6 INDUSTRIAL INSIGHTS: 126

7 MARKET OVERVIEW 128

7.1 DRIVERS 130
- 7.1.1 RISING NUMBER OF TRANSPLANT PROCEDURES 130
- 7.1.2 INCREASE IN THE TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF TRANSPLANTS 130
- 7.1.3 RISING HEALTHCARE SPENDING 130
- 7.1.4 ADOPTION OF CROSS-MATCHING AND CHIMERISM TESTING DURING PRE- AND POST-TRANSPLANTATION 131
7.2 RESTRAINTS 131
- 7.2.1 HIGH COST OF ORGAN TRANSPLANTATION 131
- 7.2.2 THE RISKS AND DIFFICULTIES OF ORGAN TRANSPLANTATION 131
7.3 OPPORTUNITIES 132
- 7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 132
- 7.3.2 RISE IN PUBLIC, PRIVATE, AND GOVERNMENT FUNDING FOR ORGAN TRANSPLANTATION 132
- 7.3.3 SURGE IN AWARENESS ABOUT THE IMPORTANCE OF ORGAN TRANSPLANTATION 133
7.4 CHALLENGES 134
- 7.4.1 ETHICAL CHALLENGES FACED DURING ORGAN TRANSPLANTATION 134
- 7.4.2 LACK OF ORGAN DONORS OR GAP BETWEEN ORGAN DONORS AND ORGANS NEEDED ANNUALLY 134

8 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE 136

8.1 OVERVIEW 137
8.2 TRANSPLANT DIAGNOSTIC INSTRUMENTS 140
- 8.2.1 AUTOMATED PIPETTORS & DISPENSERS 140
- 8.2.2 AUTOMATED SYSTEMS 140
  - 8.2.2.1 NUCLEIC ACID EXTRACTION SYSTEM 141
  - 8.2.2.2 PCR SETUP 141
  - 8.2.2.3 OTHERS 141
- 8.2.3 NGS INSTRUMENTS 141
- 8.2.4 READERS & ANALYZERS 141
- 8.2.5 TRANSPLANT DIAGNOSTIC KITS 141
  - 8.2.5.1 ASPERGILLUS SPP KITS 142
  - 8.2.5.2 P. JIROVECII KITS 142
  - 8.2.5.3 CMV KITS 142
  - 8.2.5.4 EBV KITS 142
  - 8.2.5.5 BKV KITS 143
  - 8.2.5.6 VZV KITS 143
  - 8.2.5.7 HSV1 KITS 143
  - 8.2.5.8 HSV2 KITS 143
  - 8.2.5.9 PARVOVIRUS B19 KITS 143
  - 8.2.5.10 ADENOVIRUS KITS 143
  - 8.2.5.11 ENTEROVIRUS KITS 143
  - 8.2.5.12 JCV KITS 143
  - 8.2.5.13 HHV6 KITS 143
  - 8.2.5.14 HHV7 KITS 143
  - 8.2.5.15 HHV8 KITS 143
  - 8.2.5.16 TOXOPLASMA GONDII KITS 143
  - 8.2.5.17 HEPATITIS E KITS 144
  - 8.2.5.18 OTHER KITS 144
- 8.2.6 OTHER KITS 144
8.3 TRANSPLANT DIAGNOSTIC SOFTWARE'S 144
- 8.3.1 DNA SOFTWARE 145
- 8.3.2 NGS SOFTWARE 145
- 8.3.3 DATA MANAGEMENT SOFTWARE 145
- 8.3.4 OTHER SOFTWARE'S 145
8.4 TRANSPLANT DIAGNOSTIC REAGENTS 145
- 8.4.1 MONOCLONAL ANTIBODIES 146
- 8.4.2 CYTOTOXIC CONTROLS 146
- 8.4.3 HUMAN SERUM 146
- 8.4.4 OTHER REAGENTS 146

9 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY 147

9.1 OVERVIEW 148
9.2 PCR-BASED MOLECULAR ASSAYS 151
- 9.2.1 REAL TIME PCR 151
- 9.2.2 SEQUENCE-SPECIFIC PRIMER-PCR 151
- 9.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR 152
- 9.2.4 RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP) 152
- 9.2.5 OTHER-PCR BASED MOLECULAR ASSAYS 152
9.3 SEQUENCING-BASED MOLECULAR ASSAYS 152
- 9.3.1 SANGER SEQUENCING 153
- 9.3.2 NEXT GENERATION SEQUENCING 153
- 9.3.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS. 153

10 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE 154

10.1 OVERVIEW 155
10.2 SOLID ORGAN TRANSPLANTATION 158
- 10.2.1 KIDNEY TRANSPLANTATION 158
- 10.2.2 LIVER TRANSPLANTATION 158
- 10.2.3 HEART TRANSPLANTATION 159
- 10.2.4 LUNG TRANSPLANTATION 159
- 10.2.5 PANCREAS TRANSPLANTATION 159
- 10.2.6 OTHER ORGAN TRANSPLANTATIONS 159
10.3 STEM CELL TRANSPLANTATION 159
- 10.3.1 BONE MARROW TRANSPLANT (BMT) 160
- 10.3.2 PERIPHERAL BLOOD STEM CELL TRANSPLANT 160
- 10.3.3 CORD BLOOD TRANSPLANT 160
- 10.3.4 OTHER STEM CELL TRANSPLANTS 160
10.4 SOFT TISSUE TRANSPLANTATION 160
- 10.4.1 SKIN GRAFT 161
- 10.4.2 CARTILAGE TRANSPLANTATION 161
- 10.4.3 ADRENAL AUTOGRAFTING 161
- 10.4.4 OTHER SOFT TISSUE TRANSPLANTATION. 161
10.5 BONE MARROW TRANSPLANTATION 162
- 10.5.1 AUTOLOGOUS BONE MARROW TRANSPLANT 162
- 10.5.2 ALLOGENEIC BONE MARROW TRANSPLANT 162
- 10.5.3 UMBILICAL CORD BLOOD TRANSPLANT. 163
10.6 OTHERS 163

11 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 164

11.1 OVERVIEW 165
11.2 DIAGNOSTIC APPLICATIONS 168
- 11.2.1 TRANSPLANT DIAGNOSTIC INSTRUMENT 168
  - 11.2.1.1 AUTOMATED PIPETTORS & DISPENSERS 169
  - 11.2.1.2 AUTOMATED SYSTEMS 169
  - 11.2.1.3 NGS INSTRUMENTS 169
  - 11.2.1.4 READERS & ANALYZERS 169
  - 11.2.1.5 TRANSPLANT DIAGNOSTIC KITS 169
  - 11.2.1.6 OTHERS 169
- 11.2.2 TRANSPLANT DIAGNOSTIC SOFTWARE 169
  - 11.2.2.1 DNA SOFTWARE 170
  - 11.2.2.2 NGS SOFTWARE 170
  - 11.2.2.3 DATA MANAGEMENT SOFTWARE 170
  - 11.2.2.4 OTHER SOFTWARES 170
- 11.2.3 TRANSPLANT DIAGNOSTIC REAGENT 170
  - 11.2.3.1 MONOCLONAL ANTIBODIES 171
  - 11.2.3.2 CYTOTOXIC CONTROLS 171
  - 11.2.3.3 HUMAN SERUM 171
  - 11.2.3.4 OTHER REAGENTS 171
11.3 RESEARCH APPLICATIONS 171
- 11.3.1 TRANSPLANT DIAGNOSTIC INSTRUMENT 172
  - 11.3.1.1 AUTOMATED PIPETTORS & DISPENSERS 173
  - 11.3.1.2 AUTOMATED SYSTEMS 173
  - 11.3.1.3 NGS INSTRUMENTS 173
  - 11.3.1.4 READERS & ANALYZERS 173
  - 11.3.1.5 TRANSPLANT DIAGNOSTIC KITS 173
  - 11.3.1.6 OTHERS 173
- 11.3.2 TRANSPLANT DIAGNOSTIC SOFTWARE 173
  - 11.3.2.1 DNA SOFTWARE 174
  - 11.3.2.2 NGS SOFTWARE 174
  - 11.3.2.3 DATA MANAGEMENT SOFTWARE 174
  - 11.3.2.4 OTHER SOFTWARES 174
- 11.3.3 TRANSPLANT DIAGNOSTIC REAGENT 174
  - 11.3.3.1 MONOCLONAL ANTIBODIES 175
  - 11.3.3.2 CYTOTOXIC CONTROLS 175
  - 11.3.3.3 HUMAN SERUM 175
  - 11.3.3.4 OTHER REAGENTS 175

12 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY END USER 176

12.1 OVERVIEW 177
12.2 HOSPITALS AND TRANSPLANT CENTERS 180
12.3 COMMERCIAL SERVICE PROVIDERS 180
12.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 180
12.5 OTHERS 181

13 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 182

13.1 OVERVIEW 183
13.2 DIRECT TENDER 186
13.3 RETAIL SALES 186
13.4 OTHERS 186

14 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY REGION 188

14.1 OVERVIEW 189
14.2 NORTH AMERICA 194
- 14.2.1 U.S. 206
- 14.2.2 CANADA 218
- 14.2.3 MEXICO 230
14.3 ASIA-PACIFIC 242
- 14.3.1 CHINA 256
- 14.3.2 JAPAN 268
- 14.3.3 SOUTH KOREA 280
- 14.3.4 INDIA 292
- 14.3.5 AUSTRALIA 304
- 14.3.6 SINGAPORE 316
- 14.3.7 THAILAND 328
- 14.3.8 MALAYSIA 340
- 14.3.9 INDONESIA 352
- 14.3.10 PHILIPPINES 364
- 14.3.11 REST OF ASIA-PACIFIC 376
14.4 EUROPE 377
- 14.4.1 GERMANY 392
- 14.4.2 FRANCE 404
- 14.4.3 U.K. 416
- 14.4.4 ITALY 428
- 14.4.5 RUSSIA 440
- 14.4.6 SPAIN 452
- 14.4.7 TURKEY 464
- 14.4.8 NETHERLANDS 476
- 14.4.9 SWITZERLAND 488
- 14.4.10 BELGIUM 500
- 14.4.11 REST OF EUROPE 512
14.5 SOUTH AMERICA 513
- 14.5.1 BRAZIL 525
- 14.5.2 ARGENTINA 537
- 14.5.3 REST OF SOUTH AMERICA 549
14.6 MIDDLE EAST & AFRICA 550
- 14.6.1 SOUTH AFRICA 563
- 14.6.2 SAUDI ARABIA 575
- 14.6.3 U.A.E 587
- 14.6.4 EGYPT 599
- 14.6.5 ISRAEL 611
- 14.6.6 REST OF MIDDLE EAST AND AFRICA 623

15 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: COMPANY LANDSCAPE 624

15.1 COMPANY SHARE ANALYSIS: GLOBAL 624
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 625
15.3 COMPANY SHARE ANALYSIS: EUROPE 626
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 627

16 SWOT ANALYSIS 628

17 COMPANY PROFILE 629

17.1 ABBOTT 629
- 17.1.1 COMPANY SNAPSHOT 629
- 17.1.2 REVENUE ANALYSIS 629
- 17.1.3 COMPANY SHARE ANALYSIS 630
- 17.1.4 PRODUCT PORTFOLIO 630
- 17.1.5 RECENT DEVELOPMENTS 630
17.2 THERMO FISHER SCIENTIFIC INC. 631
- 17.2.1 COMPANY SNAPSHOT 631
- 17.2.2 REVENUE ANALYSIS 631
- 17.2.3 COMPANY SHARE ANALYSIS 632
- 17.2.4 PRODUCT PORTFOLIO 632
- 17.2.5 RECENT DEVELOPMENTS 634
17.3 F. HOFFMANN LA ROCHE LTD 635
- 17.3.1 COMPANY SNAPSHOT 635
- 17.3.2 REVENUE ANALYSIS 635
- 17.3.3 COMPANY SHARE ANALYSIS 636
- 17.3.4 PRODUCT PORTFOLIO 636
- 17.3.5 RECENT DEVELOPMENT 637
17.4 TAKARA BIO INC. 638
- 17.4.1 COMPANY SNAPSHOT 638
- 17.4.2 REVENUE ANALYSIS 638
- 17.4.3 COMPANY SHARE ANALYSIS 639
- 17.4.4 PRODUCT PORTFOLIO 639
- 17.4.5 RECENT DEVELOPMENTS 639
17.5 HOLOGIC, INC 640
- 17.5.1 COMPANY SNAPSHOT 640
- 17.5.2 REVENUE ANALYSIS 640
- 17.5.3 COMPANY SHARE ANALYSIS 641
- 17.5.4 PRODUCT PORTFOLIO 641
- 17.5.5 RECENT DEVELOPMENTS 642
17.6 ADAPTIVE BIOTECHNOLOGIES 643
- 17.6.1 COMPANY SNAPSHOT 643
- 17.6.2 REVENUE ANALYSIS 643
- 17.6.3 PRODUCT PORTFOLIO 644
- 17.6.4 RECENT DEVELOPMENT 644
17.7 ALTONA DIAGNOSTICS 645
- 17.7.1 COMPANY SNAPSHOT 645
- 17.7.2 PRODUCT PORTFOLIO 645
- 17.7.3 RECENT DEVELOPMENTS 645
17.8 ARQUER DIAGNOSTICS LTD 646
- 17.8.1 COMPANY SNAPSHOT 646
- 17.8.2 PRODUCT PORTFOLIO 646
- 17.8.3 RECENT DEVELOPMENTS 647
17.9 BAG DIAGNOSTICS GMBH 648
- 17.9.1 COMPANY SNAPSHOT 648
- 17.9.2 PRODUCT PORTFOLIO 648
- 17.9.3 RECENT DEVELOPMENTS 648
17.10 BIOFORTUNA LIMITED 649
- 17.10.1 COMPANY SNAPSHOT 649
- 17.10.2 PRODUCT PORTFOLIO 649
- 17.10.3 RECENT DEVELOPMENT 649
17.11 BIOMERIEUX 650
- 17.11.1 COMPANY SNAPSHOT 650
- 17.11.2 REVENUE ANALYSIS 650
- 17.11.3 PRODUCT PORTFOLIO 651
- 17.11.4 RECENT DEVELOPMENTS 651
17.12 BIO-RAD LABORATORIES, INC. 652
- 17.12.1 COMPANY SNAPSHOT 652
- 17.12.2 REVENUE ANALYSIS 652
- 17.12.3 PRODUCT PORTFOLIO 653
- 17.12.4 RECENT DEVELOPMENT 654
17.13 BIOTYPE GMBH 655
- 17.13.1 COMPANY SNAPSHOT 655
- 17.13.2 PRODUCT PORTFOLIO 655
- 17.13.3 RECENT DEVELOPMENTS 656
17.14 CAREDX INC. 657
- 17.14.1 COMPANY SNAPSHOT 657
- 17.14.2 REVENUE ANALYSIS 657
- 17.14.3 PRODUCT PORTFOLIO 658
- 17.14.4 RECENT DEVELOPMENTS 660
17.15 CLONIT SRL 661
- 17.15.1 COMPANY SNAPSHOT 661
- 17.15.2 PRODUCT PORTFOLIO 661
- 17.15.3 RECENT DEVELOPMENT 663
17.16 DIAGNOSTICA LONGWOOD SL 664
- 17.16.1 COMPANY SNAPSHOT 664
- 17.16.2 PRODUCT PORTFOLIO 664
- 17.16.3 RECENT DEVELOPMENTS 664
17.17 DIASORIN S.P.A. 665
- 17.17.1 COMPANY SNAPSHOT 665
- 17.17.2 REVENUE ANALYSIS 665
- 17.17.3 PRODUCT PORTFOLIO 666
- 17.17.4 RECENT DEVELOPMENT 666
17.18 ELITECHGROUP 667
- 17.18.1 COMPANY SNAPSHOT 667
- 17.18.2 PRODUCT PORTFOLIO 667
- 17.18.3 RECENT DEVELOPMENTS 667
17.19 EUROFINS VIRACOR 668
- 17.19.1 COMPANY SNAPSHOT 668
- 17.19.2 PRODUCT PORTFOLIO 668
- 17.19.3 RECENT DEVELOPMENTS 669
17.20 HORIBA LTD 670
- 17.20.1 COMPANY SNAPSHOT 670
- 17.20.2 REVENUE ANALYSIS 670
- 17.20.3 PRODUCT PORTFOLIO 671
- 17.20.4 RECENT DEVELOPMENT 671
17.21 ILLUMINA, INC. 672
- 17.21.1 COMPANY SNAPSHOT 672
- 17.21.2 REVENUE ANALYSIS 672
- 17.21.3 PRODUCT PORTFOLIO 673
- 17.21.4 RECENT DEVELOPMENTS 673
17.22 IMMUCOR 674
- 17.22.1 COMPANY SNAPSHOT 674
- 17.22.2 PRODUCT PORTFOLIO 674
- 17.22.3 RECENT DEVELOPMENTS 674
17.23 LABORATORY CORPORATION OF AMERICA HOLDINGS. 675
- 17.23.1 COMPANY SNAPSHOT 675
- 17.23.2 REVENUE ANALYSIS 675
- 17.23.3 PRODUCT PORTFOLIO 676
- 17.23.4 RECENT DEVELOPMENTS 677
17.24 LUMINEX CORPORATION. (A SUBSIDIARY OF DIASORIN) 678
- 17.24.1 COMPANY SNAPSHOT 678
- 17.24.2 REVENUE ANALYSIS 678
- 17.24.3 PRODUCT PORTFOLIO 679
- 17.24.4 RECENT DEVELOPMENT 679
17.25 NANOSTRING 680
- 17.25.1 COMPANY SNAPSHOT 680
- 17.25.2 REVENUE ANALYSIS 680
- 17.25.3 PRODUCT PORTFOLIO 681
- 17.25.4 RECENT DEVELOPMENT 681
17.26 PATHONOSTICS 682
- 17.26.1 COMPANY SNAPSHOT 682
- 17.26.2 PRODUCT PORTFOLIO 682
- 17.26.3 RECENT DEVELOPMENTS 682
17.27 PRESERVATION SOLUTIONS, INC. 683
- 17.27.1 COMPANY SNAPSHOT 683
- 17.27.2 PRODUCT PORTFOLIO 683
- 17.27.3 RECENT DEVELOPMENTS 683
17.28 QIAGEN 684
- 17.28.1 COMPANY SNAPSHOT 684
- 17.28.2 REVENUE ANALYSIS 684
- 17.28.3 PRODUCT PORTFOLIO 685
- 17.28.4 RECENT DEVELOPMENTS 686
17.29 RANDOX LABORATORIES LTD. 687
- 17.29.1 COMPANY SNAPSHOT 687
- 17.29.2 PRODUCT PORTFOLIO 687
- 17.29.3 RECENT DEVELOPMENTS 688
17.30 STRYKER 689
- 17.30.1 COMPANY SNAPSHOT 689
- 17.30.2 REVENUE ANALYSIS 689
- 17.30.3 PRODUCT PORTFOLIO 690
- 17.30.4 RECENT DEVELOPMENT 690
17.31 TRANSMEDICS 691
- 17.31.1 COMPANY SNAPSHOT 691
- 17.31.2 REVENUE ANALYSIS 691
- 17.31.3 PRODUCT PORTFOLIO 692
- 17.31.4 RECENT DEVELOPMENTS 692
17.32 TRANSONIC. 693
- 17.32.1 COMPANY SNAPSHOT 693
- 17.32.2 PRODUCT PORTFOLIO 693
- 17.32.3 RECENT DEVELOPMENT 693
17.33 ZIMMER BIOMET 694
- 17.33.1 COMPANY SNAPSHOT 694
- 17.33.2 REVENUE ANALYSIS 694
- 17.33.3 PRODUCT PORTFOLIO 695
- 17.33.4 RECENT DEVELOPMENTS 695

移植診断の世界市場：業界動向と予測（～2029年）

Global Transplant Diagnostics Market - Industry Trends and Forecast to 2029

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 世界の移植診断市場：規制

第5章 主要な戦略的イニシアチブ

第6章 業界洞察：

第7章 市場概要

第8章 世界の移植診断市場：製品タイプ

第9章 世界の移植診断市場：技術別

第10章 世界の移植診断市場：移植タイプ別

第11章 世界の移植診断市場：用途別

第12章 世界の移植診断市場：エンドユーザー別

第13章 世界の移植診断市場：流通チャネル別

第14章 世界の移植診断市場：地域別

第15章 世界の移植診断市場：企業情勢